No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination
Fig 2
Maternal mRNA-1273 vaccination against SARS-CoV-2 in early pregnancy induces an antibody response that crosses the maternal–fetal interface and is detectable in fetal sera at term.
Pregnant dams were injected IM with 50 μl of PBS (n = 3 litters) or 2 μg mRNA-1273 vaccine (n = 5 litters) at E7.5. Maternal serum and pooled fetal serum from each litter were collected at E18.5, 11 days post-treatment. Anti-S and anti-RBD levels were measured by ELISA and antibody concentration was calculated based on a standard curve. Horizontal bars represent mean values. The underlying source data for this figure can be found in S1 Data. anti-RBD, anti-receptor-binding domain; anti-S, anti-spike; IM, intramuscularly; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.